Drugs / AVAXIM® 80U
AVAXIM® 80U
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT00483470 | Jun 2007 → May 2008 | hepatitis A virus infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01064141 Comparator | Jan 2010 → Sep 2012 | Dengue hemorrhagic fever | Sanofi | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVAXIM 80U | “AVAXIM® 80U” NCT01064141 ↗ |
| Known as | Avaxim | “Healthy anti-hepatitis A virus seronegative subjects aged 13 to 19 yr were randomized in three equal groups to receive two doses of Avaxim™, Epaxal®, or Havrix®, 6 to 12 months apart.” PMID 26770041 ↗ Dec 2015 |
| Known as | AVAXIM 80U Pediatric vaccine | “AVAXIM 80U Pediatric vaccine” NCT00483470 ↗ |
| Modality | Vaccine | “Hepatitis A vaccine AVAXIM 80U” NCT00483470 ↗ |